Gland Pharma Limited (NSE:GLAND)

Gland Pharma Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	64,307	64,307	56,165	56,647	36,246	44,007
Revenue Growth	14.50%	14.50%	-0.85%	56.28%	-17.64%	27.08%
Gross Profit Gross Profit Growth	39,849	39,849	31,544	31,108	17,651	21,513
Operating Income Operating Income Growth	12,059	12,059	8,721	9,715	8,844	14,000
Net Income Net Income Growth	10,273	10,273	6,985	7,725	7,810	12,117
Earnings Per Share EPS Growth	62.28	62.28	42.40	46.89	47.43	73.64
EPS Growth	46.89%	46.89%	-9.58%	-1.14%	-35.59%	16.91%

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
USA USA Growth	34,214	34,214	27,403	26,878	20,910	23,327
Europe Europe Growth	14,035	14,035	10,225	10,528	1,871	2,398
Canada, Australia and New Zealand Canada, Australia and New Zealand Growth	2,269	2,269	-	-	-	-
India India Growth	2,672	2,672	4,765	5,880	5,548	8,801
Rest of World (ROW) Rest of World (ROW) Growth	11,117	11,117	11,377	11,817	6,893	8,481
Canada Canada Growth	-	-	1,574	890.27	794.9	829.19
Australia Australia Growth	-	-	742.94	626.45	218.24	170.87
New Zealand New Zealand Growth	-	-	77.23	28.17	10.86	-
Total Total Growth	64,307	64,307	56,165	56,647	36,246	44,007

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	34,328	34,328	29,522	19,388	37,628	32,457
Total Debt Total Debt Growth	2,836	2,836	3,137	3,722	44.53	47.43
Net Cash (Debt) Net Cash Growth	31,493	31,493	26,385	15,666	37,584	32,410
Net Cash Growth	19.36%	19.36%	68.42%	-58.32%	15.96%	8.10%
Net Cash Per Share Net Cash Per Share Growth	190.92	190.92	160.15	95.10	228.22	196.97

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	10,314	10,314	9,147	9,968	3,640	7,908
Capital Expenditures CapEx Growth	-4,908	-4,908	-3,845	-3,899	-2,209	-5,113
Free Cash Flow Free Cash Flow Growth	5,406	5,406	5,302	6,069	1,430	2,794
Free Cash Flow Growth	1.97%	1.97%	-12.63%	324.27%	-48.81%	-25.71%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	61.97%	61.97%	56.16%	54.92%	48.70%	48.88%
Operating Margin	18.75%	18.75%	15.53%	17.15%	24.40%	31.81%
Pretax Margin	22.77%	22.77%	18.92%	19.99%	29.10%	36.78%
Profit Margin	15.97%	15.97%	12.44%	13.64%	21.55%	27.53%
FCF Margin	8.41%	8.41%	9.44%	10.71%	3.95%	6.35%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Aug 2, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024
Dividend Per Share Dividend Per Share Growth	20.000	20.000	18.000	20.000
Dividend Per Share Growth	11.11%	11.11%	-10.00%	-
Dividend Yield	0.80%	1.18%	1.14%	1.10%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 2, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	40.19	27.20	37.56	39.35	26.74	44.38
Forward PE	33.48	26.18	27.55	29.26	17.57	35.96
P/FCF Ratio	76.28	51.69	49.48	50.08	146.03	192.42
PS Ratio	6.41	4.35	4.67	5.37	5.76	12.22

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error